A. J. Hance, F. Basset, G. Saumon, C. Danel, D. Valeyre et al., Smoking and interstitial lung disease. The effect of cigarette smoking on the incidence of pulmonary histiocytosis X and sarcoidosis

, Ann N Y Acad Sci, vol.465, pp.643-656, 1986.

R. Watanabe, K. Tatsumi, S. Hashimoto, A. Tamakoshi, and T. Kuriyama, Clinico-epidemiological features of pulmonary histiocytosis X, Intern Med, vol.40, pp.998-1003, 2001.

G. Badalian-very, J. A. Vergilio, B. A. Degar, L. E. Macconaill, B. Brandner et al., Recurrent BRAF mutations in Langerhans cell histiocytosis, vol.116, pp.1919-1923, 2010.

N. A. Brown, L. V. Furtado, B. L. Betz, M. J. Kiel, H. C. Weigelin et al., High prevalence of somatic MAP2K1 mutations in BRAF V600E negative Langerhans cell histiocytosis, Blood, vol.124, issue.10, pp.1655-1658, 2014.

D. S. Nelson, W. Quispel, G. Badalian-very, A. G. Van-halteren, C. Van-den-bos et al., Somatic activating ARAF mutations in Langerhans cell histiocytosis, Blood, vol.123, pp.3152-3155, 2014.

M. L. Berres, K. P. Lim, T. Peters, J. Price, H. Takizawa et al., BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups, J Exp Med, vol.211, pp.669-683, 2014.

S. Von-essen, W. West, M. Sitorius, and S. I. Rennard, Complete resolution of roentgenographic changes in a patient with pulmonary histiocytosis X, Chest, vol.98, pp.765-767, 1990.

N. Mogulkoc, A. Veral, P. W. Bishop, U. Bayindir, C. A. Pickering et al., Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation, Chest, vol.115, pp.1452-1455, 1999.

A. Tazi, L. Montcelly, A. Bergeron, D. Valeyre, J. P. Battesti et al., Relapsing nodular lesions in the course of adult pulmonary Langerhans cell histiocytosis, Am J Respir Crit Care Med, vol.157, pp.2007-2010, 1998.

H. S. Suri, E. S. Yi, G. S. Nowakowski, and R. Vassallo, Pulmonary langerhans cell histiocytosis, Orphanet J Rare Dis, vol.7, p.16, 2012.

C. J. Carrera, C. Terai, M. Lotz, J. G. Curd, L. D. Piro et al., Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy, J Clin Invest, vol.86, pp.1480-1488, 1990.

A. Saven, M. L. Figueroa, and L. D. Piro, Rosenblatt JD: 2-Chlorodeoxyadenosine to treat refractory histiocytosis X, N Engl J Med, vol.329, pp.734-735, 1993.

K. C. Stine, R. L. Saylors, and L. L. Williams, DL: 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients, Med Pediatr Oncol, vol.29, pp.288-292, 1997.

A. Saven and C. Burian, Cladribine activity in adult langerhans-cell histiocytosis, Blood, vol.93, pp.4125-4130, 1999.

A. Pardanani, R. L. Phyliky, and C. Y. Li, Tefferi A: 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis, Mayo Clin Proc, vol.78, pp.301-306, 2003.

R. Lazor, B. Etienne-mastroianni, C. Khouatra, A. Tazi, V. Cottin et al., Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy, Thorax, vol.64, pp.274-275, 2009.

M. R. Aerni, M. C. Aubry, J. L. Myers, and R. Vassallo, Complete remission of nodular pulmonary Langerhans cell histiocytosis lesions induced by 2-chlorodeoxyadenosine in a non-smoker, Respir Med, vol.102, pp.316-319, 2008.

N. S. Goh, C. E. Mcdonald, D. P. Macgregor, J. J. Pretto, and G. N. Brodie, Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine, Respirology, vol.8, pp.91-94, 2003.

G. Lorillon, A. Bergeron, L. Detourmignies, S. Jouneau, B. Wallaert et al., Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis, Am J Respir Crit Care Med, vol.186, pp.930-932, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00873182

P. Soler, A. Bergeron, M. Kambouchner, O. Groussard, M. Brauner et al., Is high-resolution computed tomography a reliable tool to predict the histopathological activity of pulmonary Langerhans cell histiocytosis?, Am J Respir Crit Care Med, vol.162, pp.264-270, 2000.

B. J. Krajicek, J. H. Ryu, T. E. Hartman, V. J. Lowe, and R. Vassallo, Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis, Chest, vol.135, pp.1542-1549, 2009.

S. Harari, F. Brenot, M. Barberis, and G. Simmoneau, Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension, vol.112, pp.1142-1144, 1997.

M. Fartoukh, M. Humbert, F. Capron, S. Maitre, F. Parent et al., Severe pulmonary hypertension in histiocytosis X, Am J Respir Crit Care Med, vol.161, pp.216-223, 2000.

. Grobost, Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis, Orphanet Journal of Rare Diseases, vol.9, p.191, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02192909